Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

The effect of bezuclastinib on the pathobiology of mastocytosis: Changes in BM mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal summit trial

Tracy George, Nathan Boggs, Jay Patel, Anton Rets, Karen Moser, Madhu Menon, Amanda Pilla, Jenna Zhang, Lei Sun, Priya Singh, Raheela Soomro, Rachael Easton, Lindsay Rein

Blood (2025) 146 (Supplement 1): 1023.

https://doi.org/10.1182/blood-2025-1023

Published: 2025

Journal Articles

Efficacy and safety of the LSD1 inhibitor bomedemstat in participants with polycythemia vera (PV) resistant or intolerant to cytoreductive therapy: The Phase 2 shorespan-004 study

Lindsay Rein, Alice Livings, Rebecca Frewin, Andrew Innes, Ali Mahdi, Ciro Rinaldi, Natalia Curto-Garcia, Jennifer Vaughn, Joseph Shatzel, Paul Yeh, Jessica Flynn, Jonas Jutzi, Patricia Marinello, Michael Leahy

Blood (2025) 146 (Supplement 1): 83.

https://doi.org/10.1182/blood-2025-83

Published: 2025

Journal Articles

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Lindsay Rein, Nathan Boggs, Prithviraj Bose, Brian Modena, Vito Sabato, Karin Hartmann, Cem Akin, Tracy George, Cecilia Arana Yi, Hanneke Oude Elberink, Deepti Radia, Andreas Reiter, Miguel Piris-Villaespesa, Ingunn Dybedal, Jens Panse, Stephen Oh, Pankit Vachhani, Anthony Hunter, Mariana Castells, Cristina Bulai Livideanu, Paul van Daele, Arnold Kirshenbaum, Ivan Alvarez-Twose, Jennifer Vaughn, Minakshi Taparia, Sonia Cerquozzi, Andrzej Mital, Marek Hus, ALESSANDRA ROMANO, John Fahrenholz, Frederick Lansigan, Cristina Papayannidis, Helena Pomares, Michela Rondoni, Celalettin Ustun, Richard Herrscher, Michael Manning, Stéphane Barete, Mar Guilarte, Candido Rivera, Jonathan Bernstein, Peter Vadas, Chiara Elena, Derek McCulloch, Nina Orfali, Clodagh Keohane, Francesco Mannelli, Philippe Schafhausen, Amanda Pilla, Jenna Zhang, Lei Sun, Nisha Shah, Hina Jolin, Rachael Easton, Jessica Sachs, Frank Siebenhaar, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 80.

https://doi.org/10.1182/blood-2025-80

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States

Aaron Gerds, Lindsay Rein, Nicole Engel-Nitz, Michael Marrone, Jeffrey McPheeters, Abiola Oladapo, Purvi Suthar, Michael Vredenburg, Yong Zhu, Lucia Masarova

Blood (2025) 146 (Supplement 1): 5576.

https://doi.org/10.1182/blood-2025-5576

Published: 2025

Journal Articles

Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer

Blood (2025) 146 (Supplement 1): 2024.

https://doi.org/10.1182/blood-2025-2024

Published: 2025

Journal Articles

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Blood (2025) 146 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2025-2053

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Transformation to erythroblastic sarcoma from myeloid neoplasm with PCM1-JAK2

Catherine Luedke, Lindsay Rein

Blood (2020) 136 (9): 1113.

https://doi.org/10.1182/blood.2019004410

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The effect of bezuclastinib on the pathobiology of mastocytosis: Changes in BM mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal summit trial

Efficacy and safety of the LSD1 inhibitor bomedemstat in participants with polycythemia vera (PV) resistant or intolerant to cytoreductive therapy: The Phase 2 shorespan-004 study

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States

Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Transformation to erythroblastic sarcoma from myeloid neoplasm with PCM1-JAK2

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only